Some outside researchers were less reserved. Clinical trials using CRISPR gene editing have been underway for nearly a decade. But like most trials, they focused on broad groups of patients.

The BRILLIANCE study of EDIT-101 in Leber congenital amaurosis type 10 (LCA10) – an inherited form of blindness – was reported to be the first 'in vivo' CRISPR/Cas9 medicine to be administered ...

The CRISPR specialist said that a single 50mg infusion of NTLA-2002 – which switches off a gene involved in the potentially life-threatening inflammatory attacks that characterise HAE ...

Shares of CRISPR Therapeutics (NASDAQ:CRSP) can't seem to catch a break, now down close to 8% year to date and more than 80% ...

CRISPR Therapeutics has begun realizing sales on Casgevy, its first therapy and a joint venture with Vertex Pharmaceuticals. The company has plenty of cash to fund research and development for the ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

CRISPR Therapeutics has an approved gene-therapy treatment still in its early growth stages. One of them is CRISPR Therapeutics (NASDAQ: CRSP). Its financials haven't been looking all that ...

Collaborating with CRISPR-Cas9 co-inventor Jennifer Doudna and Jill Banfield at UC Berkeley, Steven Jacobsen, a distinguished professor of molecular, cell and developmental biology at UCLA ...

Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly ...